Enzymotec Granted Patent in Australia for INFAT Ingredient
20 Feb 2015 --- Enzymotec has announced that INFAT, the innovative ingredient that is marketed by Advanced Lipids, was granted a patent by the Australian Patent and Trademark Office for uses related to promoting development of beneficial gut flora and reducing infant crying in infants.
INFAT, a clinically proven fat ingredient (OPO) developed specifically for infant formula, incorporates the essential qualities of mothers’ milk – enabling an ideal alternative when breast milk is not available. INFAT closely mimics the composition, structure and nutritional value of natural fat in breast milk, for proper infant health, development and comfort.
“This product and its patents are an essential part of our strategy to lead the market through innovation and to provide a clear edge to our customers", says Avner Avissara, VP Sales Infant Nutrition for Enzymotec. "The patent covers the use of lipid composition, comprising a mixture of synthetic triglycerides with 15-55% palmitic for inducing a beneficiary effect on the immune system by promoting development of beneficial gut flora and for reducing the frequency and duration of infant crying" concludes Avner.
This approved patent is supported by published clinical data demonstrating that infants fed with formula containing INFAT develop similar variety of beneficial gut bacteria as breastfed babies. This promotes good health, growth, and ability to prevent infections. In addition, clinical data shows that babies nourished by formula containing INFAT cry less and for shorter duration in comparison to babies fed with regular infant formula.
